Men with metastatic castration-resistant prostate cancer (mCRPC) who progressed following initial treatment with an androgen receptor-axis-targeted agent (ARATA) had better survival when treated with docetaxel in second-line.
A total of 222 men who progressed following treatment with the ARATAs abiraterone acetate (Zytiga) or enzalutamide (Xtandi) were included in this retrospective analysis. Of these 222, 108 (48.6%) were treated with initial ARATA followed by alternative ARATA and 114 (51.4%) went from ARATA to docetaxel.
PSA response rate (42.1% vs 21.3%), median PSA progression-free survival (PFS; 7.2 vs 4.2 months) and median overall survival (OS; 17.5 vs 14.5 months) all favored patients who received docetaxel as second-line therapy.
... to read the full story